A client has decreased amniotic fluid on ultrasound. What condition is this?

Amniocentesis is an invasive prenatal procedure involving the aspiration of amniotic fluid via a transabdominal needle under ultrasound guidance. The fluid contains shed fetal skin cells and lung secretions that provide a complete fetal karyotype. It is typically performed between 15 and 20 weeks to identify chromosomal aneuploidies.

A. It evaluates placental placement: Placental location is assessed using non-invasive ultrasonography, which can identify previa or low-lying positions without entering the sac. Amniocentesis is not used for mapping uterine anatomy. Using a needle for localization purposes would pose unnecessary risks to the pregnancy.

B. It measures fetal growth: Fetal biometry, including femur length and abdominal circumference, is determined through standard ultrasound measurements. Amniocentesis provides biochemical and genetic data but cannot assess the physical size or weight gain of the fetus. Growth tracking does not require fluid sampling.

C. It screens for genetic disorders: Screening tests, like the quad screen or NIPT, only provide a statistical probability of a condition existing. Amniocentesis, however, is a diagnostic test that analyzes actual fetal DNA. It goes beyond simple screening to provide a definitive result regarding specific genetic markers.

D. It confirms or rules out genetic conditions: Because the procedure analyzes the actual fetal chromosomes, it is used to provide a conclusive diagnosis for conditions like Trisomy 21. It is the gold standard for mothers who have received a high-risk result from a screening test. This provides diagnostic certainty for the parents.

The Papanicolaou (Pap) test involves a cytological evaluation of cells collected from the transformation zone of the cervix. This procedure identifies cervical dysplasia or cellular atypia caused by persistent high-risk Human Papillomavirus (HPV) infection. Early detection of precancerous lesions, such as cervical intraepithelial neoplasia, allows for curative intervention before malignancy develops.

A. "It measures hormones.": Hormonal assays for estrogen or progesterone are typically performed via serum blood tests or specific endometrial biopsies rather than a Pap smear. A cytological smear focuses on cellular morphology rather than endocrine concentrations. It cannot diagnose menopause or other hormonal imbalances.

B. "It detects pregnancy.": Pregnancy is diagnosed by measuring human chorionic gonadotropin levels in urine or blood, or through ultrasonography. While hormonal changes of pregnancy can affect the appearance of cervical cells, a Pap smear is not a diagnostic tool for gestation. It has no role in obstetric confirmation.

C. "It checks ovulation.": Ovulation is monitored using basal body temperature charts, urinary luteinizing hormone kits, or follicular ultrasound. Cervical mucus changes can provide clues to fertility, but the laboratory analysis of a Pap smear is designed to identify malignant transformations. It does not track the ovulatory cycle.

D. "It screens for cervical cancer.": The primary clinical utility is the identification of squamous cell carcinoma or its precursors. By scraping the ectocervix and endocervix, clinicians can detect abnormal cells early. Regular screening significantly reduces maternal mortality associated with invasive cervical malignancies.